NKTR logo

NKTR
Nektar Therapeutics

8,533
Mkt Cap
$1.06B
Volume
21.00
52W High
$66.92
52W Low
$6.48
PE Ratio
-6.42
NKTR Fundamentals
Price
$58.15
Prev Close
$55.12
Open
$56.00
50D MA
$54.43
Beta
2.01
Avg. Volume
842,874.74
EPS (Annual)
-$8.68
P/B
-28.80
Rev/Employee
$1.61M
Loading...
Loading...
News
all
press releases
Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Moderate Buy" from Analysts
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are covering the firm, MarketBeat.com reports. One research...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Estimates By $1.00 EPS
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate...
MarketBeat·7h ago
News Placeholder
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting New Data from REZOLVE-AD Study of Rezpegaldesleukin...
PR Newswire·2d ago
News Placeholder
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
Zacks·3d ago
News Placeholder
Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of +35.09% and +11.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
Nektar Therapeutics Reports Third Quarter 2025 Financial Results Nektar Therapeutics Reports Third Quarter 2025 Financial Results PR Newswire SAN FRANCISCO, Nov. 6, 2025 SAN FRANCISCO, Nov. 6, 2025...
PR Newswire·4d ago
News Placeholder
Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Guardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London PR Newswire SAN...
PR Newswire·11d ago
News Placeholder
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·11d ago
News Placeholder
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets Nektar to Announce Financial Results for the Third Quarter on...
PR Newswire·13d ago

Latest NKTR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.